PHARMAXIS LTD. ANDDeposit Agreement • August 13th, 2009 • Pharmaxis Ltd. • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT dated as of November 12, 2004, as amended and restated as of September 20, 20072007, as further amended and restated as of ____________, 2009 among Pharmaxis Ltd., incorporated under the laws of the Commonwealth of Australia (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and holders from time to time of American Depositary Shares issued hereunder.
ANDDeposit Agreement • October 28th, 2004 • Pharmaxis Ltd. • New York
1. Definitions and Interpretation 2 1.1 Definitions 2 1.2 Interpretation 9 2. Put and Call Options 10 2.1 Call Option 10 2.2 Put Option 11 2.3 No Agreement for Lease 11 3. Developer’s Works 12 3.1 Not used 12 3.2 Carrying out of the Developer’s Works...Put and Call Option to Lease • November 27th, 2007 • Pharmaxis Ltd. • Pharmaceutical preparations
A = the Warehouse Space Rate multiplied by the Lettable Area of the Premises that relates to the warehouse area as specified or assumed (whichever is applicable) in the survey obtained under clause 1.4 of this Annexure H; and
Pharmaxis Ltd 1,400,000 American Depository Shares Representing 21,000,000 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • November 2nd, 2005 • Pharmaxis Ltd. • Pharmaceutical preparations • New York
Pharmaxis Ltd., an Australian limited liability company (the “Company”) proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of 1,400,000 American depository shares representing 21,000,000 ordinary shares (the “Firm ADSs”) of the Company (the “Ordinary Shares”). The respective amounts of the Firm Shares (as defined below) to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the other persons listed on Schedule II hereto (each a “Selling Shareholder” and collectively the “Selling Shareholders”) propose to grant to the Underwriters an option to purchase up to an additional 210,000 American depository shares representing 3,150,000 Ordinary Shares (the “Option ADSs”) from the Selling Shareholders for the purpose of covering over-al
Date] [Name and Address Details] Dear [ ],Employment Agreement • August 22nd, 2005 • Pharmaxis Ltd. • American depositary receipts • New South Wales
On behalf of Pharmaxis Ltd, I have pleasure in offering you a contract of employment in accordance with the particulars contained in this letter.
EXCLUSIVE LICENCE AGREEMENTExclusive Licence Agreement • August 22nd, 2005 • Pharmaxis Ltd. • American depositary receipts • Australian Capital Territory
PRAXIS PHARMACEUTICALS AUSTRALIA PTY LTD A.C.N. 082 811 630 having its registered office at Duesbarys, 60 Marcus Clarke Street, Canberra City A.C.T. 2601
PATENT LICENCE AGREEMENT made 10th October 2001 BETWEEN PRAXIS PHARMACEUTICALS AUSTRALIA PTY LTD (ACN 082 811 530) of 60 Marcus Clarke Street, Canberra, ACT 2601 (‘PRAXIS’) AND CENTRAL SYDNEY AREA HEALTH SERVICE of QE II Building. RPAH Campus,...Patent Licence Agreement • August 22nd, 2005 • Pharmaxis Ltd. • American depositary receipts • New South Wales
A CSAHS has knowledge in respect of powder technologies for use in the management of respiratory disease. Aspects of this knowledge are protected by patents and patent applications in a number of countries.
Form of Employment Contract entered into with Company OfficersEmployment Agreement • September 16th, 2008 • Pharmaxis Ltd. • Pharmaceutical preparations
On behalf of Pharmaxis Ltd (“Company”), I have pleasure in offering you a further contract of employment in accordance with the particulars contained in this letter. If you accept this offer, the terms and conditions set out in this letter will supersede and replace all prior employment agreements and understandings. Any accrued employee entitlements you may have prior to the acceptance of this letter will not be affected by your acceptance of this letter.
PHARMACEUTICALS PARTNERSHIPS PROGRAM P3 FUNDING AGREEMENT GENERAL CONDITIONSFunding Agreement • August 22nd, 2005 • Pharmaxis Ltd. • American depositary receipts • Australian Capital Territory
ARTICLE 1.DEFINITIONS. 1 SECTION 1.01AMERICAN DEPOSITARY SHARES. 1 SECTION 1.02 CHE SS 1 SECTION 1.03 COM MISSION. 1 SECTION 1.04 COM PANY. 2 SECTION 1.05 CUST ODIAN. 2 SECTION 1.06 DEPO SIT AGREEMENT 2 SECTION 1.07 DEPOSIT, DELIVER, EXECUTE, ISSUE,...Deposit Agreement • August 31st, 2005 • Pharmaxis Ltd. • Pharmaceutical preparations • New York
General ConditionsGrant Agreement • August 22nd, 2005 • Pharmaxis Ltd. • American depositary receipts
Form: 07L LEASE Leave this space clear. Affix Licence: 01-05-028 additional Licensee: Makinson & d’Apice New South Wales Real Property Act 1900 pages to the top left-hand corner. PRIVACY NOTE: Section 31B of the Real Property Act 1900 (RP Act)...Lease Agreement • December 6th, 2006 • Pharmaxis Ltd. • Pharmaceutical preparations • New South Wales
SERVICE AGREEMENTService Agreement • August 22nd, 2005 • Pharmaxis Ltd. • American depositary receipts • Australian Capital Territory
